Enquirer Consulting Group

Reachable Buyer Map

Prepared for Dan Walles · TraceLink · August 2026
The pharmaceutical supply chain is one of the few markets that enumerates itself. Every node has to register somewhere, which means the buyer set can be counted rather than estimated. This is that count for the United States: the tiers, who signs inside each one, and roughly how many companies sit there. It describes the market rather than your business, and there is nothing to buy at the end of it.
Drug manufacturers and label holders
The node everything else is measured against, and the one with the clearest register behind it. It includes the virtual companies that own the label and outsource every physical step, which is a different buyer from a company running its own plants.
Who signs: VP of supply chain, head of serialization, VP of quality, director of regulatory affairs, and the IT owner for enterprise applications.
7,500 to 8,000
distinct US drug firms, spread across roughly 9,800 registered establishments
Contract manufacturers, packagers and repackagers
Individually small, collectively the largest count of obligated companies after the pharmacy tier. Each one carries the compliance load of every customer it packs for, so the work lands on operations rather than on a compliance function that may not exist.
Who signs: chief operating officer, director of packaging operations, quality director, and the client services lead who fields customer audits.
2,000 to 2,800
registered contract manufacturing, repackaging and relabeling establishments
Wholesale distributors and third party logistics
The connective tier. Small in number and heavy in transaction volume, so the buying question is throughput and exception handling rather than whether a rule applies. Also the tier most likely to already run a system and be judging a replacement.
Who signs: VP of distribution, the named compliance officer, the program owner for traceability, and the head of IT.
1,200 to 1,800
distinct US wholesale distributors and logistics providers operating under state licensing
Dispensers: pharmacies and health systems
The largest count on this page by an order of magnitude and the most misleading one. The register counts locations and legal entities. The decisions are made a long way above them, inside chains, health systems, buying groups and the services companies that act for independents.
Who signs: director of pharmacy operations, chief pharmacy officer, VP of supply chain at a health system, and at the independent end, the owner.
68,000 to 75,000
registered US pharmacy organizations; the layer that actually decides is a few hundred
Medical device and diagnostics manufacturers
A parallel market with its own identification rules and its own registers. The traceability conversation is younger here, which means fewer incumbents and more companies still deciding how to run it rather than who to replace.
Who signs: VP of quality and regulatory, the identification program owner, director of supply chain, and the head of manufacturing systems.
12,500 to 13,500
registered US device establishments, of which roughly 5,000 to 5,500 are manufacturers
Clinical supply and specialty channels
Trial supply, cold chain and specialty distribution sit across the tiers above rather than inside one of them. Worth stating plainly: there is no public register of clinical supply teams, so this group is reached by name and by study rather than counted.
Who signs: head of clinical supply chain, director of trial operations, and the logistics lead who owns the temperature controlled lanes.
No clean register
identified study by study; the difficulty is exactly why the segment stays underworked

Where the openings are

1
The pharmacy tier is a counting illusion. Sixty eight to seventy five thousand registered organizations resolve to a few hundred real decisions once chains, health systems, buying groups and the services companies acting for independents are collapsed. A channel aimed at the count burns itself out. A channel aimed at the decision layer is a finite, nameable list that can be covered completely and revisited on a schedule.
2
Two buyers, and they do not share a calendar. Quality and regulatory own the obligation. Supply chain operations and IT own the integration and the exception queue. Reaching one and not the other is the most common way a deal in this market stalls at the point where it should close. That is a coverage design problem, and it is fixed up front by naming both seats in every target account.
3
The small end of every tier is where the register is complete and the coverage usually is not. Two thousand plus contract packagers and repackagers, and several hundred smaller distributors, are all obligated, and in a market like this one the small end is rarely carried by a named account owner anywhere. They are enumerable and they are reachable. They read as quiet because they are seldom worked, not because they are uninterested.
4
The rules move, and the buying moment moves with them. Every phase in, extension and exemption resets which tier is under pressure this quarter. A channel that runs continuously catches those companies in the weeks they are actually deciding. A channel built around conference season meets them either months early or months late.
Built from public registries, counts banded deliberately. Establishment files count registered sites rather than companies, so firm level and site level figures differ on purpose. Pharmacy figures come from provider enumeration data, which counts organizations rather than decision makers. Clinical supply is not enumerated anywhere public and is described rather than counted.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com